These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 16001947)
1. The ODAC chronicles: Part 5. Prostate cancer endpoints. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Jun; 5(3):405-10. PubMed ID: 16001947 [No Abstract] [Full Text] [Related]
2. The ODAC chronicles: part 1. My first ODAC experience. Grillo-López AJ Expert Rev Anticancer Ther; 2004 Oct; 4(5):709-12. PubMed ID: 15485306 [No Abstract] [Full Text] [Related]
3. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431 [No Abstract] [Full Text] [Related]
4. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516 [No Abstract] [Full Text] [Related]
5. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art? Grillo-López AJ Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323 [No Abstract] [Full Text] [Related]
6. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Fleming MT; Morris MJ; Heller G; Scher HI Nat Clin Pract Oncol; 2006 Dec; 3(12):658-67. PubMed ID: 17139317 [TBL] [Abstract][Full Text] [Related]
8. Cancer vaccines on the horizon. Jones D Nat Rev Drug Discov; 2007 May; 6(5):333-4. PubMed ID: 17539052 [No Abstract] [Full Text] [Related]
9. The ODAC Chronicles: Part 6a. ODAC's structure and function. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Aug; 5(4):573-7. PubMed ID: 16111457 [No Abstract] [Full Text] [Related]
10. Surrogate and mediating endpoints: current status and future directions. Prentice RL J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455 [No Abstract] [Full Text] [Related]
11. The ODAC Chronicles: part 6b. ODAC's structure and function. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Oct; 5(5):753-6. PubMed ID: 16221044 [No Abstract] [Full Text] [Related]
12. The hazards of intermediate endpoints. Beer TM; Ryan CW Cancer; 2007 Nov; 110(9):1877-9. PubMed ID: 17849427 [No Abstract] [Full Text] [Related]
13. The ODAC Chronicles: part 7. Tale of two goals. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Dec; 5(6):939-41. PubMed ID: 16336083 [No Abstract] [Full Text] [Related]
14. Endpoints for assessing drug activity in clinical trials. Pazdur R Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Collette L; Burzykowski T; Schröder FH Eur J Cancer; 2006 Jul; 42(10):1344-50. PubMed ID: 16730974 [TBL] [Abstract][Full Text] [Related]
18. Clinical endpoints for drug development in prostate cancer. Ramiah V; George DJ; Armstrong AJ Curr Opin Urol; 2008 May; 18(3):303-8. PubMed ID: 18382240 [TBL] [Abstract][Full Text] [Related]
19. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. D'Amico A BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of clinically localized prostate cancer. Part I--observation or treatment?]. Szelachowska J; Kornafel J; Gisterek I Pol Merkur Lekarski; 2006 Dec; 21(126):594-7. PubMed ID: 17405305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]